SCHEMBL6792396

SCHEMBL6792396

CC1(C(O)c2ccc(-c3ccc4ccccc4c3)cc2)NC(=O)NC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 5/20 0.46
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
UGT2B7 P16662 1/20 0.39
LPL P06858 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
GSTP1 P09211 1/20 0.36
UTS2R Q9UKP6 2/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
ALOX5 P09917 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
HDAC4 P56524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6827189 0.89 ESR1 (0.44) PTGER3ESR1ESR2HSD17B1HSD17B2
SCHEMBL6827181 0.89 ESR1 (0.44) PTGER3ESR1ESR2HSD17B1HSD17B2
SCHEMBL6791153 0.86 MMP2 (0.41)
SCHEMBL6791227 0.86 MMP2 (0.41)
SCHEMBL6789361 0.86 MMP2 (0.41)
SCHEMBL8337588 0.84 FASN (0.38) PTGER3
SCHEMBL8342628 0.83 NPC1 (0.47) AKR1C3AKR1C2
SCHEMBL6824386 0.83 CA2 (0.41) PTGER3CA2
SCHEMBL6824389 0.83 CA2 (0.41) PTGER3CA2
SCHEMBL8339982 0.82 PGR (0.41) AKR1C3AKR1C2HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 PTGER3 452/4885ESR1 2264/4885ESR2 858/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PTGER3 2233/4885ESR1 729/4885ESR2 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.